Skip to main content
Premium Trial:

Request an Annual Quote

Assurex Pharmacogenomics Tests to Use Luminex xTag Technology

NEW YORK (GenomeWeb) – Luminex today announced that its xTAG universal tag technology has been selected for use in Assurex Health's GeneSight neuropsychiatric pharmacogenomics tests.

Gene Sight compares patients' DNA signatures with known pharmacology in order to predict how they might react to medicines used to treat depression, post-traumatic stress disorder, anxiety, bipolar disease, schizophrenia, and other behavioral health conditions.

According to Luminex, its technology will enhance the processing speed and capacity of the Gene Sight tests. "In addition, the flexibility of the Luminex platform will allow us to add new biomarkers as our needs continue to expand," Assurex COO Donald Wright said in a statement.

Specific terms of the arrangement were not disclosed.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.